

DEPOSITARY RECEIPTS

February 16, 2018

NEW DR ANNOUNCEMENT

Biofrontera AG

Biofrontera is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused by exposure to sunlight that results in sun damage to the skin. The Company's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of basal cell carcinoma in the European Union.

Effective Date:	February 16, 2018
Country of Incorporation:	Germany
Exchange:	NASDAQ Stock Market
Type of ADR Program:	Sponsored - Level III
Ticker Symbol:	BFRA
CUSIP Number:	09075G105
Ratio (DR:ORD):	1 : 2
Underlying Share Description:	Ordinary
Industry Classification:	Pharma. & Biotech.
Custodian(s) :	The Bank of New York Mellon SA/NV

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Ravi Davis / Rick Maehr
DR Broker Liaison
adrdesk@bnymellon.com
+1 212 815 2267

London

Jacek Jankowski
DR Broker Liaison
jacek.jankowski@bnymellon.com
+44 207 163 7427

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.